Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK‐positive anaplastic large‐cell lymphoma refractory to chemotherapy and brentuximab vedotin

Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK‐positive anaplastic large‐cell lymphoma refractory to chemotherapy and brentuximab vedotin

Abstract This is the first case report of alectinib as a bridge to allo‐SCT in a patient with ALK‐positive ALCL refractory to both conventional chemotherapies and BV. This report offers a ray of hope for a condition with poor prognosis.

Bibliographic Details
Main Authors: Ritsuko Nakai, Suguru Fukuhara, Akiko Miyagi Maeshima, Sung‐Won Kim, Yuta Ito, Shunsuke Hatta, Tomotaka Suzuki, Sayako Yuda, Shinichi Makita, Wataru Munakata, Tatsuya Suzuki, Dai Maruyama, Koji Izutsu
Format: Article
Language:English
Published: Wiley 2019-12-01
Series:Clinical Case Reports
Subjects:
alectinib
ALK‐positive ALCL
hematopoietic stem cell transplantation
Online Access:https://doi.org/10.1002/ccr3.2543

Internet

https://doi.org/10.1002/ccr3.2543

Similar Items